baha the information company

baha is a leading provider of real-time market data, financial news, technology and solutions for the financial industry. baha offers real-time data terminals for professionals, global financial market data covering over 12 million financial instruments on more than 150 exchanges, as well as 24/7 breaking news with global coverage and free web and mobile apps. From a total of around 200 real-time data providers worldwide, only Reuters 1851, Bloomberg 1981 and now baha in 2021 were named after the founder.

Axsome Therapeutics Inc/ US05464T1043 /

2024-09-04 10:00:00 PM	Chg. +5.9100	Volume	Bid1:25:30 AM	Ask1:25:30 AM	High	Low
95.5600USD	+6.59%	1.15 mill. Turnover: 80.9 mill.	88.0000Bid Size: 200	96.5000Ask Size: 2,000	96.8500	88.4380

GlobeNewswire 08-27 Axsome Therapeutics to Participate in Investor Conferences in September

GlobeNewswire 08-21 Axsome Therapeutics Reaches Agreement to Dismiss Sunosi® (Solriamfetol) Patent Litigation with Sando...

GlobeNewswire 08-11 AXSOME ALERT: Bragar Eagel & Squire, P.C. is Investigating Axsome Therapeutics, Inc. on Behalf of Lo...

GlobeNewswire 08-05 Axsome Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update

GlobeNewswire 08-01 Compass Pathways announces second quarter 2024 financial results and business highlights

GlobeNewswire 07-25 Global Fibromyalgia Treatment Market Projected To Reach $3.86 Billion By 2031 as Positive Growth Tre...

GlobeNewswire 07-11 Axsome Therapeutics to Report Second Quarter 2024 Financial Results on August 5

GlobeNewswire 06-26 Compass Pathways appoints Lori Englebert as Chief Commercial Officer

GlobeNewswire 06-05 Axsome Therapeutics Settles Sunosi® (solriamfetol) Patent Litigation with Unichem Laboratories

GlobeNewswire 06-04 Axsome Therapeutics Joins the American Migraine Foundation to Highlight Unmet Treatment Needs During...

GlobeNewswire 06-03 Axsome Therapeutics Supports Alzheimer’s & Brain Awareness Month

GlobeNewswire 05-30 Axsome Therapeutics to Participate in Upcoming Investor Conferences

GlobeNewswire 05-29 Axsome Therapeutics Highlights Data on Solriamfetol Demonstrating Improvement in Cognitive Function ...

GlobeNewswire 05-28 Axsome Therapeutics Presents Data from Multiple Programs at the 2024 American Society of Clinical Ps...

GlobeNewswire 05-08 Axsome Therapeutics to Present at Upcoming Investor Conferences

GlobeNewswire 05-06 Axsome Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update

GlobeNewswire 05-01 Axsome Therapeutics Recognizes May as Mental Health Awareness Month

GlobeNewswire 05-01 AXSOME ALERT: Bragar Eagel & Squire, P.C. is Investigating Axsome Therapeutics, Inc. on Behalf of Lo...

GlobeNewswire 04-18 AXSOME ALERT: Bragar Eagel & Squire, P.C. is Investigating Axsome Therapeutics, Inc. on Behalf of Lo...

GlobeNewswire 04-15 Axsome Therapeutics Highlights Innovative Neuroscience Portfolio at the American Academy of Neurolog...

GlobeNewswire 04-12 AXSOME ALERT: Bragar Eagel & Squire, P.C. is Investigating Axsome Therapeutics, Inc. on Behalf of Lo...

GlobeNewswire 04-10 Axsome Therapeutics to Report First Quarter 2024 Financial Results on May 6

GlobeNewswire 04-04 AXSOME ALERT: Bragar Eagel & Squire, P.C. is Investigating Axsome Therapeutics, Inc. on Behalf of Lo...

GlobeNewswire 04-01 Axsome Therapeutics Initiates ENGAGE Phase 3 Trial of Solriamfetol for the Treatment of Binge Eating...

GlobeNewswire 03-26 AXSOME ALERT: Bragar Eagel & Squire, P.C. is Investigating Axsome Therapeutics, Inc. on Behalf of Lo...

Axsome Therapeutics Inc/ US05464T1043 /

If you wish to receive reply to your feedback, please provide your email address.